╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ End of last exacerbation less than 6 weeks prior   │ End of last exacerbation less than 6 weeks prior   │
│ to screening/re-screening visit                    │ to screening/re-screening visit.                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ability to comply with completion of electronic    │ Ability to comply with completion of electronic    │
│ diary                                              │ diary.                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically significant intercurrent illnesses      │ Clinically significant intercurrent illnesses      │
│ (except for respiratory or liver disease secondary │ (except for respiratory or liver disease secondary │
│ to AAT deficiency), including: cardiac, hepatic,   │ to AAT deficiency), including: cardiac, hepatic,   │
│ renal, endocrine, neurological, hematological,     │ renal, endocrine, neurological, hematological,     │
│ neoplastic, immunological, skeletal or other) that │ neoplastic, immunological, skeletal or other) that │
│ in the opinion of the investigator, could          │ in the opinion of the investigator, could          │
│ interfere with the safety, compliance or other     │ interfere with the safety, compliance or other     │
│ aspects of this study                              │ aspects of this study. Patients with well-         │
│                                                    │ controlled, chronic diseases could possibly be     │
│                                                    │ included after consultation with the treating      │
│                                                    │ physician and the sponsor.                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of at least two moderate or severe         │ History of at least two moderate or severe         │
│ exacerbations that required change in treatment    │ exacerbations that required change in treatment    │
│ (antibiotics, systemic steroids, hospitalization)  │ (antibiotics, systemic steroids, hospitalization)  │
│ in the last 18 months prior to date of screening , │ in the last 18 months prior to date of screening , │
│ with at least one of these occurring within the    │ with at least one of these occurring within the    │
│ last 12 months prior to screening                  │ last 12 months prior to screening.                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in another clinical trial within 30  │ Participation in another clinical trial within 30  │
│ days prior to baseline visit                       │ days prior to baseline visit.                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Woman of child-bearing potential not taking        │ Woman of child-bearing potential not taking        │
│ adequate contraception deemed reliable by the      │ adequate contraception deemed reliable by the      │
│ investigator                                       │ investigator.                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ No significant abnormalities in serum hematology,  │ No significant abnormalities in serum hematology,  │
│ serum chemistry and serum inflammatory /           │ serum chemistry and serum inflammatory /           │
│ immunogenic markers according to the Principal     │ immunogenic markers according to the Principal     │
│ Investigator's judgment, taking into               │ Investigator's judgment, taking into               │
│ considerations the potential effects of the AAT    │ considerations the potential effects of the AAT    │
│ deficiency                                         │ deficiency.                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Negative for HBsAg and for antibodies to HCV,      │ Negative for HBsAg and for antibodies to HCV,      │
│ HIV-1                                              │ HIV-1.                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence of psychiatric/mental disorder or any     │ No Match                                           │
│ other medical disorder which might impair the      │                                                    │
│ patient's ability to give informed consent or to   │                                                    │
│ comply with the requirements of the study protocol │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ If a report of past CT scan is not available at    │ Diagnosis of emphysema confirmed by CT scan. If a  │
│ site documenting then a CT scan is to be performed │ report of past CT scan is not available at site    │
│ at screening                                       │ documenting then a CT scan is to be performed at   │
│                                                    │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of life-threatening allergy, anaphylactic  │ No Match                                           │
│ reaction, or systemic response to human plasma     │                                                    │
│ derived products                                   │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ FEV1 ≥ 80% or FEV1 < 20% of predicted value post-  │ No Match                                           │
│ bronchodilator                                     │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any lung surgery within the past two years         │ Any lung surgery within the past two years.        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnancy or lactation                             │ Pregnancy or lactation.                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inability to attend scheduled clinic visits and/or │ Inability to attend scheduled clinic visits and/or │
│ comply with the study protocol                     │ comply with the study protocol.                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ No significant abnormalities in urinalysis         │ No significant abnormalities in urinalysis         │
│ according to the Principal Investigator's          │ according to the Principal Investigator's          │
│ judgment, taking into considerations the potential │ judgment, taking into considerations the potential │
│ effects of the AAT deficiency                      │ effects of the AAT deficiency.                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Non-pregnant, non-lactating female patients, whose │ Non-pregnant, non-lactating female patients, whose │
│ screening pregnancy test is negative and who are   │ screening pregnancy test is negative and who are   │
│ using contraceptive methods deemed reliable by the │ using contraceptive methods deemed reliable by the │
│ investigator, or who are at least 2 years post-    │ investigator, or who are at least 2 years post-    │
│ menopausal or surgically sterilized                │ menopausal or surgically sterilized.               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patient with record of congenital AAT deficiency   │ Patient with record of congenital AAT deficiency   │
│ of phenotype PiZZ (homozygote) or other rare       │ of phenotype PiZZ (homozygote) or other rare       │
│ phenotypes related to AAT deficiency and with AAT  │ phenotypes related to AAT deficiency and with AAT  │
│ serum level ≤ 11 micromole                         │ serum level ≤ 11 micromole. For patients receiving │
│                                                    │ IV AAT augmentation therapy the serum AAT level    │
│                                                    │ threshold does not apply.                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ FEV1/SVC <70% of predicted value post              │ FEV1/SVC <70% of predicted value post              │
│ bronchodilator (SVC is slow VC) and FEV1 < 80% of  │ bronchodilator (SVC is slow VC) and FEV1 < 80% of  │
│ predicted value post-bronchodilator                │ predicted value post-bronchodilator                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of ongoing viral infection with HCV, HBV  │ Evidence of ongoing viral infection with HCV, HBV  │
│ and/or HIV                                         │ and/or HIV.                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any other factor that, in the opinion of the       │ Any other factor that, in the opinion of the       │
│ investigator, would prevent the patient from       │ investigator, would prevent the patient from       │
│ complying with the requirements of the protocol    │ complying with the requirements of the protocol.   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active smoking during the last 12 months from      │ Active smoking during the last 12 months from      │
│ screening date                                     │ screening date.                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of lung transplant                         │ History of lung transplant.                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosis of emphysema confirmed by CT scan        │ Diagnosis of emphysema confirmed by CT scan. If a  │
│                                                    │ report of past CT scan is not available at site    │
│                                                    │ documenting then a CT scan is to be performed at   │
│                                                    │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ No significant abnormalities in ECG per            │ No significant abnormalities in ECG per            │
│ investigator judgment                              │ investigator judgment.                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who stopped IV augmentation treatment 6   │ No Match                                           │
│ months prior to screening date and will not re-    │                                                    │
│ start this treatment for the course of the study   │                                                    │
│ will be considered naïve                           │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Male or female patients at least 18 years of age   │ Male or female patients at least 18 years of age.  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Well-controlled, chronic diseases could possibly   │ No Match                                           │
│ be included after consultation with the treating   │                                                    │
│ physician and the sponsor                          │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ability to self-administer inhaled AAT             │ Ability to self-administer inhaled AAT.            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ For patients receiving IV AAT augmentation therapy │ Patient with record of congenital AAT deficiency   │
│ the serum AAT level threshold does not apply       │ of phenotype PiZZ (homozygote) or other rare       │
│                                                    │ phenotypes related to AAT deficiency and with AAT  │
│                                                    │ serum level ≤ 11 micromole. For patients receiving │
│                                                    │ IV AAT augmentation therapy the serum AAT level    │
│                                                    │ threshold does not apply.                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ AAT deficient patients who are either naïve (not   │ AAT deficient patients who are either naïve (not   │
│ receiving IV augmentation therapy) or AAT          │ receiving IV augmentation therapy) or AAT          │
│ deficient patients (receiving IV augmentation      │ deficient patients (receiving IV augmentation      │
│ therapy), if they have been stable on regular      │ therapy), if they have been stable on regular      │
│ therapy for at least 3 months prior to the         │ therapy for at least 3 months prior to the         │
│ screening visit and are willing to continue the    │ screening visit and are willing to continue the    │
│ same regime throughout this trial                  │ same regime throughout this trial. Note that only  │
│                                                    │ sites in Germany can recruit patients who are      │
│                                                    │ currently being treated with IV AAT.Patients who   │
│                                                    │ stopped IV augmentation treatment 6 months prior   │
│                                                    │ to screening date and will not re-start this       │
│                                                    │ treatment for the course of the study will be      │
│                                                    │ considered Naïve.                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Only sites in Germany can recruit patients who are │ No Match                                           │
│ currently being treated with IV AAT                │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ On any thoracic surgery waiting list               │ On any thoracic surgery waiting list.              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ FEV1/SVC ≥ 70%                                     │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able and willing to sign an informed consent       │ Able and willing to sign an informed consent.      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of alcohol abuse or history of alcohol    │ Evidence of alcohol abuse or history of alcohol    │
│ abuse or illegal and/or legally prescribed drugs   │ abuse or illegal and/or legally prescribed drugs.  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ IgA Deficiency                                     │ IgA Deficiency                                     │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛